CheckMate-032 was a phase I/II trial of nivolumab (anti-PD-1 antibody) alone or nivolumab plus ipilimumab (anti-CTLA-4 antibody) in recurrent SCLC patients showing acceptable toxicity and clinically meaningful responses with 1-year overall survival rate of 27 and 48% for nivolumab alone and nivolumab plus ipilimumab arms respectively. This evidence concerns the gene PDCD1 and small cell lung carcinoma.